UK Markets closed

32,884 Orion Corporation A shares converted into B shares

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ORION CORPORATION STOCK EXCHANGE RELEASE 8 JULY 2021 at 9.00 EEST

32,884 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 32,884 A shares have been converted into 32,884 B shares. The conversion has been entered into the Trade Register on 8 July 2021.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 35,006,523 A shares and 106,127,755 B shares. The number of votes of the company's shares is after the conversion 806,258,215.

Orion Corporation

Jari Karlson

CFO

Olli Huotari

SVP, Corporate Functions


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting